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ABSTRACT
Introduction Acute malnutrition (AM) is a continuum 
condition, arbitrarily divided into moderate and severe 
AM (SAM) categories, funded and managed in separate 
programmes under different protocols. Optimising acute 
MAlnutrition (OptiMA) treatment aims to simplify and 
optimise AM management by treating children with mid- 
upper arm circumference (MUAC) <125 mm or oedema 
with one product—ready- to- use therapeutic food—at 
a gradually tapered dose. Our main objective was to 
compare the OptiMA strategy with the standard nutritional 
protocol in children 6–59 months presenting with MUAC 
<125 mm or oedema without additional complications, as 
well as in children classified as uncomplicated SAM (ie, 
MUAC <115 mm or weight- for- height Z- score (WHZ) <−3 
or with oedema).
Methods and analysis This study was a non- inferiority, 
individually randomised controlled clinical trial conducted 
at community level in the Democratic Republic of Congo. 
Children 6–59 months presenting with MUAC <125 mm 
or WHZ <−3 or with bipedal oedema and without medical 
complication were included after signed informed 
consent in outpatient health facilities. All participants 
were followed for 6 months. Success in both arms was 
defined at 6 months post inclusion as being alive, not 
acutely malnourished per the definition applied at inclusion 
and without an additional episode of AM throughout the 
6- month observation period. Recovery among children 
with uncomplicated SAM was the main secondary 
outcome. For the primary objective, 890 participants were 
needed, and 480 children with SAM were needed for the 
main secondary objective. We will perform non- inferiority 
analyses in per- protocol and intention- to- treat basis for 
both outcomes.
Ethics and dissemination Ethics approvals were 
obtained from the National Health Ethics Committee of 
the Democratic Republic of Congo and from the Ethics 
Evaluation Committee of Inserm, the French National 
Institute for Health and Medical Research (Paris, France). 
We will submit results for publication to a peer- reviewed 
journal and disseminate findings in international and 
national conferences and meetings.
Trial registration number NCT03751475. Registered 
19 September 2018, https:// clinicaltrials. gov/ ct2/ show/ 
NCT03751475.
INTRODUCTION
Acute malnutrition (AM) affects an estimated 
50 million children under 5 years of age, 
including 16.6 million severe acute malnutri-
tion (SAM) cases, and is an underlying cause 
of 800 000 deaths each year worldwide.1 2 
Strengths and limitations of this study
 ► This is the first study of a mid- upperarm circum-
ference (MUAC)- based malnutrition treatment pro-
tocol with gradually tapered dose of ready- to- use 
therapeutic food (RUTF) that uses an individually 
randomised controlled design.
 ► The main outcome takes into account sustained 
health and nutrition status at 6 months after inclu-
sion, including post- recovery relapse and sponta-
neous recovery for children who are not eligible for 
RUTF supplementation.
 ► The methodology used for randomisation (ie, strat-
ification based on WHO definition of severe acute 
malnutrition (SAM)) allows for two robust analy-
ses: first, how all children with MUAC <125 mm or 
weight- for- height Z- score <−3 or oedema respond 
under OptiMA (Optimising acute MAlnutrition); and 
second, how children only meeting the WHO defini-
tion of SAM respond.
 ► This trial is not a multisite study and only takes place 
in one country, the Democratic Republic of Congo.
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Other estimation methods based on incidence instead of 
prevalence suggest the caseload for this major public 
health concern may be substantially higher.3 4 One quarter 
of all acutely malnourished children are in Africa and as 
many as 2 million severely wasted children were reported 
in the Democratic Republic of Congo (DRC) in 2018.5
Since the publication of the United Nations (UN) Joint 
Statement in 2009, millions of children have received treat-
ment for SAM via standard community- based manage-
ment6 7 with >80% of children recovering in outpatient 
care.8 Despite more than a decade of expanded access 
to treatment, coverage of nutrition programmes remains 
remarkably low, as few as 20% of wasted children actu-
ally receive treatment9 10 and the World Bank estimates 
that it would take an additional US$6.3 billion per year to 
reach a coverage of 80%.11 There is, therefore an urgent 
need to better allocate available resources through the 
simplification and optimisation of current AM proto-
cols. Adapting programming in three key aspects of case 
management may allow improved access to treatment for 
acutely malnourished children.
First, AM is as a continuum condition, but it is arbi-
trarily divided into moderate acute malnutrition (MAM) 
and SAM categories. This distinction results in separate 
programmes overseen by different UN agencies and 
using different protocols and products—ready- to- use 
supplementary food (RUSF) or fortified- blended flours 
for children with MAM and ready- to- use therapeutic food 
(RUTF) for children with SAM. This complicates supply 
chain, delivery of care, data collection, and creates confu-
sion and extra work for caregivers and health workers 
alike.12 In practice, only SAM treatment is often available, 
whereas identification and treatment of children earlier 
in the wasting process would lead to fewer hospitalisa-
tions and deaths. The treatment of MAM has been shown 
to reduce mortality risk by more than 10%.13
Second, current case definitions to determine 
programme eligibility are unnecessarily complicated, 
using two independent anthropometric criteria: mid- 
upper arm circumference (MUAC) or weight- for- height 
Z- score (WHZ). WHZ alone or in combination with 
MUAC does not offer a clear advantage for identifying 
children at near- term risk of death over MUAC alone.14 
MUAC- only programming is expanding as evidence accu-
mulates that weight gain and MUAC gain track each other 
and respond to treatment in similar ways.15–17 MUAC is, 
therefore, becoming a stand- alone practical tool for all 
phases of nutrition programming: screening, admission, 
monitoring recovery and determining discharge. Further-
more, the simplicity of MUAC bracelets makes it possible 
to screen children not only in the community but also at 
home.18
Third, therapeutic food rations could be allocated 
more efficiently. The RUTF ration for treating SAM 
(130–200 kcal/kg/day) is paradoxical. The amount of 
RUTF prescribed remains constant or even increases with 
weight gain up until discharge (ie, as the child recovers 
from AM), even though weight and MUAC gain is 
maximal during the first 2–3 weeks of supplementation.19 
Consequently, gradual dose reduction seems to be a more 
rational use of RUTF which accounts for a large propor-
tion of total malnutrition programme costs.20
Results on integrating SAM and MAM treatment in a 
single MUAC- based protocol using only RUTF at a grad-
ually reduced dose were first published in 2015. This 
cluster- randomised trial conducted in Sierra Leone 
found high recovery rates, a reduced caseload of chil-
dren with SAM, a better coverage rate and reduced RUTF 
costs when compared with the standard protocol.21 More 
recently, a non- inferiority randomised trial in Burkina 
Faso showed that the reduction of the RUTF dose after 
the first 2 weeks results in similar weight gain velocity and 
recovery rates as with the standard dose given throughout 
SAM treatment.22
Our research consortium developed the Optimising 
treatment for Acute Malnutrition (OptiMA) strategy that 
simplifies the definition of AM to MUAC <125 mm or the 
presence of bipedal oedema, and uses a single product 
for treatment—RUTF—at a gradually reduced dose 
based on a child’s weight and MUAC status (see table 1). 
The OptiMA strategy was first implemented in a proof- 
of- concept single- arm trial in Burkina Faso and showed 
a recovery rate that exceeded national and international 
Sphere23 standards for both SAM and MAM (86.3%; 
95% CI 85.4% to 87.2%) with excellent health worker 
adherence to the new RUTF dosage table.24 However, 
recovery of children admitted at MUAC <115 mm was 
poorer than anticipated (70.4%; 95 % CI 67.5% to 73.5%) 
which necessitated a randomised controlled trial to 
compare OptiMA to current national malnutrition proto-
cols. We therefore planned this individually randomised 
non- inferiority clinical trial to compare the OptiMA 
strategy to the DRC nutritional standard protocol in chil-
dren 6–59 m with uncomplicated AM.
We hypothesised that the OptiMA strategy would be as 
effective as the current DRC national protocol currently in 
use, in children 6 to 59 years old as judged by the success 
rate in the treatment of uncomplicated SAM and MAM 
at 6 months postrandomisation and in terms of recovery 
rate in the treatment of uncomplicated SAM.
Objectives
The principal objective aims to determine, 6 months 
after inclusion, whether the OptiMA strategy leads a 
success rate that is non- inferior to that of the standard 
DRC protocol in use in the same outpatient health facil-
ities. The definition of ‘success’ is described in the Study 
outcomes section.
The main secondary objective is to determine whether 
the recovery rate of children with uncomplicated SAM 
according to the current WHO definition25 (ie, MUAC 
<115 mm or WHZ <–3 or bilateral oedema) managed 
under the OptiMA protocol is non- inferior to that of the 
national standard protocol, anticipating that such chil-
dren treated under OptiMA will receive a smaller overall 
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RUTF ration than those treated under the DRC national 
protocol.
Other secondary objectives include description and 
comparison between the two study arms of the following 
outcomes: RUTF consumption, relapse after nutritional 
recovery, outcomes compared with international Sphere 
references, recovery and success in children who present 
with both wasting and stunting at inclusion, and to 
describe the nutritional and clinical status of children 
hospitalised while enrolled in the study.
METHODS
This protocol follows the Standard Protocol Items: 
recommendations for Interventional Trials (SPIRIT) 
guidelines.26
Design
This study is a non- inferiority individually randomised 
controlled clinical trial conducted at health centres and 
in the community. Participants were randomly assigned to 
either the OptiMA strategy arm (intervention=OptiMA) or 
the national standard protocol arm (control=Standard).
Study setting
The trial took place in the Kamuesha health zone, Kasai 
province in DRC and was nested within a medical and 
nutritional emergency humanitarian project launched 
by Alliance for International Medical Action (ALIMA) in 
May 2018. The Kamuesha health zone is located in a trop-
ical forest and is particularly isolated.
ALIMA supports the DRC Ministry of Health (MoH) 
in 9 of 26 health areas in the Kamuesha health zone 
to address a nutritional crisis occurring after a 2 years 
of armed conflict with significant population displace-
ment.27 During the trial preparation phase, we visited 
all health areas covered by ALIMA and selected four as 
research sites based on demographic, epidemiological 
and logistical criteria in addition to observations provided 
by local stakeholders. According to projections from the 
last census, the four health areas chosen covered a popu-
lation of 65 000 people, including 12 000 children aged 
6 to 59 months, spread over 60 villages. Health facilities 
included in the study were the four community- based 
primary health centres of these four health areas in addi-
tion to the general hospital of Kamuesha district which 
was used for referring participants with medical compli-
cations. Most (n=49) villages were less than 10 km away 
from the primary health centres while 11 were more than 
15 km away.
Eligibility criteria
Children aged 6–59 months, residing in one of the 
four health areas and meeting at least one of the three 
following AM criteria were eligible for inclusion in the 
trial: MUAC <125 mm and/or bilateral pitting oedema 
(+/++) and/or WHZ <−3. Children with a medical 
Table 1 Wasting definition, treatment products, calculation of dosage and recovery definition in the DRC national and OptiMA 
protocol
National DRC protocol OptiMA protocol
SAM MAM Acute malnutrition
Wasting 
definition
MUAC <115 mm or 
WHZ <−3 or bipedal 
oedema
MUAC (115–124 mm)
or −3 <WHZ <−2





Super cereal plus 200 g/day 
(~1000 kcal/day)


















According to the 
weight
Fixed amount, regardless of weight 
or MUAC status
According to MUAC status and weight
Recovery 
definition
MUAC ≥125 mm or 
WHZ ≥−1.5 (for 2 
consecutive weeks)
MUAC ≥125 mm or WHZ ≥−1.5
If after recovery from SAM: MUAC 
≥125 mm and WHZ ≥−1.5 and 
discharge after 3 months
MUAC >125 mm for 2 consecutive weeks
And no oedema for 2 consecutive weeks And No oedema for 2 consecutive weeks 
And minimum 4 weeks in programme and good 
clinical health 
DRC, Democratic Republic of Congo; MAM, moderate acute malnutrition; MUAC, mid- upper arm circumference; OptiMA, Optimising acute 
MAlnutrition; RUSF, ready- to- use supplementary food; RUTF, ready- to- use therapeutic food ; SAM, sever acute malnutrition; WHZ, weight- 
for- height Z- score.
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complication requiring hospitalisation, no appetite, 
oedema grade +++, with a known allergy to milk, peanuts 
or RUTFs, with a known chronic pathology (such as sickle 
cell anaemia, trisomy 21, congenital heart disease, neuro-
logical disease), or already enrolled in a malnutrition 
programme were excluded from the trial. Two categories 
of children were included in the trial but not eligible for 
randomisation for ethical concerns. First, children with 
WHZ <−3 and MUAC >125 mm without oedema were 
systematically included in the control arm, as they were 
not RUTF eligible according to the wasting definition 
of the OptiMA strategy. Second, children with a sibling 
already enrolled in the study were systematically allocated 
to the study arm of the index sibling.
Study outcomes
The primary outcome will be judged by a binary composite 
indicator. Children classified as ‘success’ fulfil all of the 
following criteria: alive, not acutely malnourished per the 
definition applied at inclusion and not having an addi-
tional episode of AM throughout the 6- month observation 
period. All other children are classified as ‘unsuccessful’.
The main secondary outcome will be determined 
among children in both arms of the trial who meet 
the current WHO definition of SAM at inclusion. For 
this subgroup, recovery is defined in both arms, after a 
4- week minimum duration of treatment as, clinically well 
(an axillary temperature <37.5°C), absence of bipedal 
oedema and an MUAC >125 mm for the OptiMA arm or 
MUAC >125 mm or WHZ >−1.5 for the standard arm, for 
two consecutive weeks. Additional secondary outcomes 
are listed in table 2.
Sample size considerations
We determined the sample size for the principal objec-
tive using an expected success rate of 55% and for the 
secondary main objective an expected recovery rate of 
85%. Both of these hypotheses are based on recovery, 
death, default and relapse rates available in the litera-
ture for severely and moderately wasted children supple-
mented with RUTF and/or RUSF in DRC and other 
African contexts.28 29 We also considered spontaneous 
recovery rate documented for MAM children without 
treatment in the standard arm.30 During the preparation 
phase, we twice visited the four sites included in the study 
and found that the standard MAM treatment programme 
was either non- functional or partially functional.
We assumed a margin of non- inferiority of 10%, the 
same as the three other non- inferiority trials assessing 
simplified treatment strategies with RUTF for wasted 
children.31–33
To demonstrate non- inferiority of the OptiMA strategy 
compared with standard protocol, 890 and 490 partici-
pants were required for the principal and main secondary 
objectives, respectively, with 80% power at a unilateral 
significance level of 2.5% and with an inflation of 15% 
to account for unexploitable data. We estimated 15% of 
incomplete data in the light of the challenging reality of 
this study setting where families are regularly confronted 
with barriers to receiving healthcare, insecurity and 
displacement.
Randomisation
The trial statistician established and maintained a confi-
dential randomisation list. Randomisation was done in 
blocks and was stratified at the study site by the severity of 
AM according to the WHO definition. This double strat-
ification allows for recruitment of comparable groups of 
SAM and non- SAM children and for simultaneous rando-
misation at the four sites. The trial data scientist inte-
grated the list into a randomisation software developed 
for the trial that was programmed on four tablet devices. 
This software assigned a treatment arm by sequentially 
drawing from this list each time a randomisation proce-
dure was completed. Once the sample size for the primary 
objective was reached, only WHO- SAM cases continued 
to be enrolled and randomised until the sample size 
required for the main secondary objective was attained.
Patient and public involvement
To ensure that the trial was understood, accepted and 
implemented in accordance with local customs and prac-
tices, meetings to explain trial eligibility and procedures 
were organised with community representatives in each 
village and with nutrition actors prior to recruitment. 
During the trial’s active phase, regular oral presentations 
were held at the local level. We intend to disseminate the 
findings through meetings with community representa-
tives and national nutrition actors.
Enrolment and informed consent procedure
Prior to enrolment, all community health workers, 
nurse research officers and MoH medical staff impli-
cated in the study were trained on the trial protocol, 
standardised operating procedures and the correct use 
of tools developed for data collection. Nurse research 
officers were specifically trained to enrol and randomise 
study participants, and monitor home visits and outpa-
tient visits at the health centre. Children were recruited 
through monthly active mass malnutrition screenings 
in each of the 60 villages. Concomitantly, children 
attending outpatient consultations at the four study 
health centres underwent routine passive malnutrition 
screening and were enrolled in the trial if eligible. In 
both active and passive screening, a nurse research 
officer, assisted by a community health worker, collected 
anthropometric (weight, height, MUAC, WHZ) and 
clinical (presence of oedema) information on eligible 
children. Children then underwent a medical consul-
tation to determine whether they met the criteria for 
study inclusion. A standard operating procedure (see 
online supplemental file 1) for assessing child anthro-
pometry (weight, height, MUAC and oedema) were 
observed in each site. For each eligible child, the care-
taker was given a study information sheet detailing the 
study’s aims, treatment protocols, study duration, and 
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  Success Composite: alive, not acutely 
malnourished per the definition 
applied at inclusion and no 
additional episode of acute 
malnutrition throughout the 6- 
month observation period
Children with MUAC 
<125 mm or WHZ <−3 or 
bipedal oedema at inclusion
Proportion 6 months post- 
inclusion
Main secondary
  Recovery Composite: in both arms, a 
4- week minimum duration of 
RUTF treatment, an axillary 
temperature <37.5°C, absence 
of bipedal oedema, and for 
the OptiMA arm a MUAC 
>125 mm and for the standard 
arm MUAC >125 mm or WHZ 
>−1.5, for two consecutives 
weeks
Children with MUAC 
<115 mm or WHZ <−3 or 
bipedal oedema at inclusion
Proportion Throughout the 6 
months needed for 
study completion 
after RUTF treatment 
has been initiated at 
inclusion
Secondary
  Consumption of 
RUTF by children with 
acute malnutrition at 
inclusion
Sachets of RUTF consumed Children with MUAC 
<125 mm or WHZ <−3 or 
bipedal oedema at inclusion
Median/mean 6 months post- 
inclusion
  Consumption of 
RUTF by children who 
recovered from SAM
Sachets of RUTF consumed Children with MUAC 
<115 mm or WHZ <−3 or 
bipedal oedema at inclusion 
who recovered
Median/mean At the visit when 
recovery is determined 
  Total weight gain 
and daily weight 
gain in children who 
recovered from SAM 
Total weight gain (g) and weight 
gain in g/kg/day
Children with MUAC 
<115 mm or WHZ <−3 or 
bipedal oedema at inclusion 
who recovered
Median/mean At the visit when 
recovery is determined
 
  Total MUAC gain 
and daily MUAC 
gain in children who 
recovered from SAM
Total MUAC gain in mm and 
MUAC gain in mm/day
Children with MUAC 
<115 mm or WHZ <−3 or 
bipedal oedema at inclusion 
who recovered
Median/mean At the visit when 
recovery is determined 
  Total length of RUTF 
treatment in children 
who recovered from 
SAM
Total number of days with 
RUTF treatment
Children with MUAC 
<115 mm or WHZ <−3 or 
bipedal oedema at inclusion 
who recovered
Median/mean At the visit when 
recovery is determined
Non- response in 
children with SAM 
Absence of recovery status Children with MUAC 
<115 mm or WHZ <−3 or 
bipedal oedema at inclusion
Proportion After 12 and 16 weeks 
of nutritional follow- 
up of SAM episode at 
inclusion 
  Relapse to a new 
episode of SAM 
(WHO definition)
Children with MUAC<115 or 
WHZ <-3 or oedema after 
RUTF treatment
Children with MUAC 
<115 mm or WHZ <-3 or 
bipedal oedema at inclusion 
recovered
Proportion During 3 months 
following recovery 
from SAM episode at 
inclusion
MUAC, mid- upper arm circumference; OptiMA, optimizing acute malnutrition; RUTF, ready- to- use therapeutic food; SAM, severe acute 
malnutrition; WHZ, weight- for- height Z- score.
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frequency of clinic visits and community follow- up. This 
information was explained orally in Tshiluba (local 
language). Caretakers who agreed to participate in the 
study indicated their consent by signing (signature or 
fingerprint) a written consent form. When caretakers 
were not able to read or write, an impartial witness 
oversaw the consent process and attested to the care-
taker’s consent by signing the consent form on her/
his behalf. All caretakers were informed about their 
right to withdraw from the study at any time without 
affecting the quality of medical care provided to their 
children. All medical care and nutritional treatment 
were provided free of charge, regardless of participa-
tion in the study.
Intervention and follow-up
In the intervention arm, all children with a MUAC 
<125 mm or oedema were supplemented with RUTF, 
according to the OptiMA dosage table based on the 
progression of MUAC and weight gain during recovery 
(ie, RUTF dosage is gradually reduced as a child’s 
weight and MUAC increases) (see table 1). The OptiMA 
RUTF dosage table provides for a daily caloric intake of 
170–200, 125–190 and 50–166 kcal/kg/day in children 
with a MUAC <115 mm, between 115 and 119 mm and 
>119 mm, respectively. Children with oedema received 
the same RUTF ration as children with MUAC <115 mm 
until oedema resolved, at which point their ration was 
determined by MUAC and weight (see online supple-
mental file 2).
In the control arm, children included with MUAC 
<115 mm and/or WHZ <−3 and/or nutritional oedema 
were treated with RUTF, according to the DRC national 
protocol dosage table which is based on a child’s weight 
at each visit (ie, RUTF dosage gradually increases as a 
child’s weight increases). The DRC protocol provides a 
RUTF daily caloric intake of 150–200 kcal/kg/day during 
the entire treatment course until recovery in children 
with SAM and one sachet of RUSF per day (500 kcal/day) 
in children with MAM.
The differences between the OptiMA and the DRC 
national standard protocols, summarised in table 1, 
concern treatment eligibility, definitions of recovery and 
relapse, the type of therapeutic food provided and RUTF 
dosage calculation. All other aspects of the standard 
nutrition protocol were applied to all children in both 
arms. All cases of SAM according to the WHO definition 
received amoxicillin 50–100 mg/kg/day for 7 days, and 
all children received vitamin A and deworming regard-
less of anthropometry. In both arms, a malaria rapid 
test was systematically performed at inclusion and at any 
point during follow- up when a child presented with clin-
ical signs of malaria. If positive, an artemisinin combina-
tion treatment was prescribed for the child. At the time 
of the study, the HIV national programme was not func-
tional in the Kamuesha health zone, hence children with 
SAM were not offered HIV counselling and testing, as is 
recommended.25
All participants were monitored for 6 months after 
inclusion (see figure 1). While in the treatment phase, 
children came to the health centres once a week for 
outpatient consultations (or every 2 weeks for those chil-
dren living in villages more than 14 km from the health 
centre). On discharge from treatment, or immediately 
after inclusion for children with MAM who did not receive 
RUTF in the standard arm, children were consulted every 
2 weeks in their villages until 6 months post- inclusion was 
completed. During village visits, a nurse research officer 
assisted by one or two community health workers moni-
tored the anthropometric and clinical status of these 
children, referring any child who needed nutritional or 
medical care to either the primary healthcare facility or 
to the Kamuesha general hospital.
Blinding
This was an unblinded trial. Caretakers and study 
personnel were aware of study arm allocation for partic-
ipating children due to differences in anthropometric 
criteria and RUTF ration. On inclusion, the nurse 
research officer gave each trial participant’s caretaker a 
card specifying the nutritional strategy being followed 
by the child. Caretakers were asked to present this card 
in the event of an unplanned outpatient consultation or 
hospital admission during the study period. In this way, 
nurses or doctors at any health facility were able to iden-
tify the nutritional treatment being followed by the child.
Data collection and management
After obtaining individual informed consent, all socio-
demographic characteristics, anthropometric and clin-
ical data collected during follow- up were documented 
in the case report forms by the research officers and the 
healthcare providers trained specifically for this study. All 
data entered into the database were securely transferred 
and stored on a server hosted by PAC- CI, a satellite for 
the French National Agency for Research on AIDS and 
Viral Hepatitis in Abidjan, Côte d’Ivoire which served as 
the methodology and coordinating centre for this study. 
All data and any adverse events, including deaths and 
hospitalisations, were rigorously monitored both on- site 
and remotely, according to the data monitoring plan. 
To ensure patient safety and data integrity, the method-
ology and coordinating centre continuously supervised 
data management activities, and the senior scientific 
project leader and investigators performed field visits on 
a regular basis. If children failed to attend follow- up visits, 
the community health worker living in the village visited 
the household to check on the child, to determine the 
reasons for absence and to encourage the caretakers to 
adhere to the planned health centre visit schedule.
Statistical analyses
All statistical analyses will be performed using RStudio 
Software (Boston, Massachusetts, USA) as specified by 
the data analysis plan published on  ClinicalTrials. gov 
prior to performing any analysis. Statistical tests will be 
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carried out bilaterally with an alpha risk of 5% and unilat-
erally with an alpha risk of 2.5% for the non- inferiority 
analysis. Qualitative variables will be described in terms 
of numbers, percentages and provided with CIs when 
relevant. If necessary, comparisons of qualitative variables 
will be made using χ2 or Fisher exact tests. Quantitative 
variables will be described in terms of mean, SD and CI 
or median, range and IQR. If necessary, comparisons 
of quantitative variables will be made using Student’s, 
Wilcoxon’s or the Kruskal- Wallis tests, depending on the 
distribution of the variable of interest. Time delay type 
variables will be described in terms of the incidence of 
occurrence, and the probability of occurrence over time, 
estimated by the Kaplan- Meier method. If necessary, prob-
ability comparisons will be made using log- rank tests, or 
proportional risk models, after verification of the assump-
tion of proportionality of risks.
Primary analysis of the primary and secondary main 
outcomes
Descriptive summaries of participant characteristics by 
arm at inclusion will be tabulated. Participants included 
in the main analyses will be described according to the 
diagram defined by CONSORT (Consolidated Standards 
of Reporting Trials) recommendations.34 The occurrence 
of the primary ‘success’ and the secondary main outcome 
‘recovery’ will be compared between the two randomisa-
tion arms. These two comparisons will be performed both 
by ‘intention- to- treat’ basis and on a ‘per- protocol’ basis. 
Non- inferiority analyses will be performed on these two 
outcomes. Only if non- inferiority for these two outcomes 
is demonstrated will the other secondary analyses will be 
performed, and, if appropriate, as a superiority analysis. 
Superiority will be particularly sought for cost outcomes 
related to RUTF cost- efficiency.
Sensitivity analysis of the primary outcome
First, rates of ‘success’ and ‘recovery’ will be analysed 
based on all available data. Then a sensitivity analysis 
will be performed using the maximum bias method. 
In this analysis, deceased participants, those who have 
withdrawn their consent, who have been transferred to 
another health facility or have been lost to follow- up, will 
be considered to have systematically failed to the allo-
cated treatment.
Safety
The trial was monitored monthly by an international 
steering committee and quarterly by a national steering 
committee where any adverse events were presented. No 
interim analysis was planned before the final analyses. 
The data safety monitoring board could have requested 
Figure 1 Schedule of enrolment, interventions and assessments OptiMA- DRC overview. *Monthly active screening in 60 
villages and passive screening during outpatient visit in four health centres. **Weekly (for those living in villages at 14 km or less 
from the health centre) or bimonthly (for those living in villages more than 14 km from the health centre) outpatient visits at health 
centre for participants with ready- to- use therapeutic food (RUTF) supplementation. ***Bimonthly home visits for children without 
RUTF supplementation. d, day; DRC, Democratic Republic of Congo; m, month; OptiMA, optimising acute malnutrition.
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an interim analysis if it deemed it necessary for patient 
safety.
A child in intervention arm could be removed from the 
study for two reasons: (1) if he or she had two episodes of 
>5% weight loss during the course of treatment and (2) 
if he or she was not SAM at inclusion but deteriorated to 
SAM during RUTF supplementation.
Ethics and dissemination
The study was conducted in accordance with the Decla-
ration of Helsinki. We obtained ethical approval with 
annual renewal from DRC National Ethics Committee 
(CNES) (94/CNES/BN/PMMF/2018) and from the 
Ethics Evaluation Committee of the French National Insti-
tute for Health and Medical Research (Inserm) (18-545). 
The final version of the protocol, version 3.1, dated 22 
October 2019, is available for sharing on request and 
included three minor amendments to protocol version 
2.0 (dated 6 March 2019) and version 3.0 (dated 18 April 
2019) which was shared with national and international 
ethical committees and did not require a new authorisa-
tion. In November 2019, the CNES performed an audit at 
each site and then renewed approval (152/CNES/BN/
PMMF/2019) for the continuation of the trial. All data 
were anonymised when entered into the database using 
unique identification numbers. We intend to dissem-
inate the results regardless of positive or negative find-
ings broadly via peer- reviewed publication, conferences 
and clinical networks targeting academics, policy- makers, 
clinicians and caregivers.
DISCUSSION
This trial was anchored in the following foundational 
principle: the need to merge MAM and SAM nutritional 
care into a single programme using one anthropo-
metric admission criterion and one type of therapeutic 
food to simplify care for families, health workers and 
programme managers. This study will contribute to a 
developing evidence- base composed of similar studies 
already published or currently in progress in Sierra 
Leone, Burkina Faso, South Sudan and Kenya.31 35 Given 
that the risk profile associated with low anthropometry 
is highly contextual, it is important to conduct similar 
trials in multiple settings. This will be the first such trial 
in DRC, where we expect a higher proportion of oedem-
atous malnutrition than is typically found in East or West 
Africa. Furthermore, this is an individually randomised 
trial that will monitor outcomes for an extended period, 
4–5 months, after nutritional recovery. It also includes a 
group of children rarely studied but common in everyday 
practice: MAM children who do not receive supplemental 
food. This study design should allow for robust conclu-
sions not only regarding the non- inferiority of OptiMA 
compared with a typical standard SAM protocol but also 
an evaluation of the incidence of SAM among children 
with MAM. This trial will also document outcomes of 
sustained health and nutrition status over a longer period 
than previous trials.
Furthermore, the stratified randomisation of children 
with SAM according to the WHO definition will shed some 
light on the clinical effects of the OptiMA strategy for this 
specific category of children. This inclusion strategy will 
also help to determine the segment of children with SAM 
defined by only WHZ with MUAC >125 mm, in Kasaï prov-
ince where stunting prevalence in children is higher than 
anywhere else in the DRC.36
Trial status
The recruitment phase began in July 2019 and ended in 
22 January 2020. The estimated completion date for this 
study is September 2020.
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